Cassava Sciences (SAVA) Expected to Announce Quarterly Earnings on Wednesday

Cassava Sciences (NASDAQ:SAVA - Get Free Report) will likely be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect Cassava Sciences to post earnings of ($0.99) per share for the quarter.

Cassava Sciences Stock Performance

NASDAQ:SAVA traded down $0.15 during trading hours on Friday, reaching $2.55. The stock had a trading volume of 1,100,019 shares, compared to its average volume of 1,279,754. Cassava Sciences has a 12-month low of $2.23 and a 12-month high of $42.20. The stock has a 50 day simple moving average of $2.53 and a 200 day simple moving average of $16.42. The stock has a market cap of $122.68 million, a P/E ratio of -1.85 and a beta of -0.95.

Insider Activity at Cassava Sciences

In related news, CFO Eric Schoen sold 59,800 shares of Cassava Sciences stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $3.86, for a total value of $230,828.00. Following the completion of the transaction, the chief financial officer now directly owns 11,500 shares in the company, valued at approximately $44,390. The trade was a 83.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered Cassava Sciences from a "buy" rating to a "neutral" rating and set a $116.00 price objective for the company. in a report on Tuesday, November 26th.

Cassava Sciences Company Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.